{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:45:12Z","timestamp":1788911112953,"version":"build-2803163510"},"reference-count":37,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sickle cell hemoglobin SC (HbSC) disease is the second most frequent sickle cell disease (SCD) genotype after sickle cell anemia (HbSS). Globally, \u223c55 000 newborns with HbSC are delivered annually, with the highest HbC gene frequency in West Africa. In Ghana, 40% of adults visiting the Ghana Institute of Clinical Genetics SCD clinic have HbSC. Unlike HbSS, hydroxyurea use is not routinely recommended for individuals with HbSC because of the perceived high-risk to benefit ratio. To test the hypothesis that at least 5% of adults with HbSC will meet the American Society of Hematology criteria for severe disease, we conducted a retrospective descriptive cohort study of all individuals with HbSC (\u226518 years) who visited the clinic in 2019. Adults with HbSC aged from 18 to 45 years were selected. We identified a comparison group of 639 individuals with HbSS and matched the frequency based on the age and sex of individuals with HbSC. Severe disease was defined as a history of \u22653 SCD-associated moderate or severe pain episodes per year, history of acute chest syndrome, and severe symptomatic chronic anemia that interferes with daily activities or quality of life. The study end points were the proportion of individuals with SCD who met the definition of severe disease and were eligible for hydroxyurea. In total, 64 of 639 (10.0%) individuals with HbSC met the eligibility criteria for hydroxyurea therapy compared with 154 of 639 (24.1%) individuals with HbSS. Less than 1% and 3% of individuals with severe HbSC and HbSS, respectively, were routinely prescribed with hydroxyurea in this tertiary care medical center.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009049","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T15:56:34Z","timestamp":1676649394000},"page":"3312-3319","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":24,"title":["Most adults with severe HbSC disease are not treated with hydroxyurea"],"prefix":"10.1182","volume":"7","author":[{"given":"William Kwesi","family":"Ghunney","sequence":"first","affiliation":[{"name":"1Ghana Institute of Clinical Genetics, Korle-Bu, Accra, Ghana"},{"name":"2Department of Haematology, Korle-Bu Teaching Hospital, Accra, Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia Vicky","family":"Asare","sequence":"additional","affiliation":[{"name":"1Ghana Institute of Clinical Genetics, Korle-Bu, Accra, Ghana"},{"name":"2Department of Haematology, Korle-Bu Teaching Hospital, Accra, Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3211-7137","authenticated-orcid":false,"given":"John Benaiah","family":"Ayete-Nyampong","sequence":"additional","affiliation":[{"name":"3Department of Haematology, University of Ghana Medical School, Accra, Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3836-1376","authenticated-orcid":false,"given":"Samuel Antwi","family":"Oppong","sequence":"additional","affiliation":[{"name":"4Department of Obstetrics and Gynaecology, University of Ghana Medical School, Accra, Ghana"},{"name":"5Department of Obstetrics and Gynaecology, Korle-Bu Teaching Hospital, Accra, Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7258-0073","authenticated-orcid":false,"given":"Mark","family":"Rodeghier","sequence":"additional","affiliation":[{"name":"6Consultatnt Statistician, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0574-1604","authenticated-orcid":false,"given":"Michael R.","family":"DeBaun","sequence":"additional","affiliation":[{"name":"7Vanderbilt-Meharry Sickle Cell Disease Center of Excellence, Nashville, TN"},{"name":"8Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1646-4470","authenticated-orcid":false,"given":"Edeghonghon","family":"Olayemi","sequence":"additional","affiliation":[{"name":"1Ghana Institute of Clinical Genetics, Korle-Bu, Accra, Ghana"},{"name":"2Department of Haematology, Korle-Bu Teaching Hospital, Accra, Ghana"},{"name":"3Department of Haematology, University of Ghana Medical School, Accra, Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"issue":"22","key":"2023071115274711400_bib1","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood-2010-01-251348","article-title":"The inherited diseases of hemoglobin are an emerging global health burden","volume":"115","author":"Weatherall","year":"2010","journal-title":"Blood"},{"issue":"9861","key":"2023071115274711400_bib2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(12)61229-X","article-title":"Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates","volume":"381","author":"Piel","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"2023071115274711400_bib3","first-page":"4","article-title":"Differences in the clinical and genotypic presentation of sickle cell disease around the world","volume":"15","author":"Saraf","year":"2014","journal-title":"Paediatr Respir Rev"},{"key":"2023071115274711400_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/6161270","article-title":"Burden of sickle cell disease in Ghana: the Korle-Bu experience","volume":"2018","author":"Asare","year":"2018","journal-title":"Adv Hematol"},{"issue":"3","key":"2023071115274711400_bib5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ajh.10140","article-title":"Outcome in hemoglobin SC disease: a four-decade observational study of clinical, hematologic, and genetic factors","volume":"70","author":"Powars","year":"2002","journal-title":"Am J Hematol"},{"issue":"2","key":"2023071115274711400_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ajh.25356","article-title":"Multidisciplinary care results in similar maternal and perinatal mortality rates for women with and without SCD in a low-resource setting","volume":"94","author":"Oppong","year":"2019","journal-title":"Am J Hematol"},{"issue":"2","key":"2023071115274711400_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2215\/CJN.03940415","article-title":"Kidney disease among patients with sickle cell disease, hemoglobin SS and SC","volume":"11","author":"Drawz","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 1","key":"2023071115274711400_bib8","article-title":"Unusually high prevalence of silent stroke and cerebral vasculopathy in hemoglobin SC disease","volume":"134","author":"Sathi","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2023071115274711400_bib9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/bjh.14444","article-title":"Knowledge insufficient: the management of haemoglobin SC disease","volume":"176","author":"Pecker","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"2023071115274711400_bib10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0268-960X(03)00003-1","article-title":"The paradox of hemoglobin SC disease","volume":"17","author":"Nagel","year":"2003","journal-title":"Blood Rev"},{"issue":"4","key":"2023071115274711400_bib11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/bjh.13625","article-title":"Cohort study of adult patients with haemoglobin SC disease: clinical characteristics and predictors of mortality","volume":"171","author":"Gualandro","year":"2015","journal-title":"Br J Haematol"},{"issue":"2","key":"2023071115274711400_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.blre.2015.08.005","article-title":"The role of blood rheology in sickle cell disease","volume":"30","author":"Connes","year":"2016","journal-title":"Blood Rev"},{"issue":"6","key":"2023071115274711400_bib13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A\u00a0phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023071115274711400_bib14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023071115274711400_bib15","first-page":"2","article-title":"Hydroxyurea and transfusion therapy sickle cell disease","author":"Creary","year":"2014","journal-title":"A\u00a0Pocket Guid Clin Washington DC Am Soc Hematol"},{"issue":"1","key":"2023071115274711400_bib16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.21550","article-title":"Definitions of the phenotypic manifestations of sickle cell disease","volume":"85","author":"Ballas","year":"2010","journal-title":"Am J Hematol"},{"key":"2023071115274711400_bib17","first-page":"195","volume-title":"Sickle Cell Disease","author":"Oppong","year":"2021"},{"issue":"2","key":"2023071115274711400_bib18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/bjh.14383","article-title":"Guidelines on red cell transfusion in sickle cell disease Part II: indications for transfusion","volume":"176","author":"Davis","year":"2017","journal-title":"Br J Haematol"},{"issue":"6","key":"2023071115274711400_bib19","doi-asserted-by":"crossref","first-page":"e1775","DOI":"10.1542\/peds.2014-2986","article-title":"Evidence-based management of sickle cell disease: expert panel report, 2014","volume":"134","year":"2014","journal-title":"Pediatrics"},{"issue":"6","key":"2023071115274711400_bib20","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"issue":"8","key":"2023071115274711400_bib21","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1182\/blood.V99.8.3014","article-title":"Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease","volume":"99","author":"Pegelow","year":"2002","journal-title":"Blood"},{"issue":"20","key":"2023071115274711400_bib22","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023071115274711400_bib23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ajh.24255","article-title":"Effects of hydroxyurea treatment for patients with hemoglobin SC disease","volume":"91","author":"Luchtman-Jones","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"2023071115274711400_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/ajh.2830470203","article-title":"Improvement of sickle cell anemia by iron-limited erythropoiesis","volume":"47","author":"Castro","year":"1994","journal-title":"Am J Hematol"},{"issue":"6","key":"2023071115274711400_bib25","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2018-10-880575","article-title":"Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis","volume":"133","author":"DeBaun","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2023071115274711400_bib26","doi-asserted-by":"crossref","first-page":"932","DOI":"10.7326\/0003-4819-148-12-200806170-00220","article-title":"National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease","volume":"148","author":"Brawley","year":"2008","journal-title":"Ann Intern Med"},{"issue":"2","key":"2023071115274711400_bib27","doi-asserted-by":"crossref","first-page":"765","DOI":"10.4314\/ahs.v21i2.36","article-title":"Level of utilization and provider-related barriers to the use of hydroxyurea in the treatment of sickle cell disease patients in jos, north-central Nigeria","volume":"21","author":"OD Ofakunrin","year":"2021","journal-title":"Afr Health Sci"},{"key":"2023071115274711400_bib28","doi-asserted-by":"crossref","first-page":"765958","DOI":"10.3389\/fgene.2021.765958","article-title":"Barriers to therapeutic use of hydroxyurea for sickle cell disease in Nigeria: a cross-sectional survey","volume":"12","author":"Okocha","year":"2021","journal-title":"Front Genet"},{"key":"2023071115274711400_bib29","unstructured":"Agency GN . Hydroxyurea, sickle cell medicine, now available in Ghana---Ministry Of Health. MoH News. 2019. Accessed 13 September 2022. https:\/\/www.moh.gov.gh\/hydroxyurea-sickle-cell-medicine-now-available-in-ghana."},{"key":"2023071115274711400_bib30","unstructured":"Ghana increases minimum wage for 2021 and 2022. Accessed 13 September 2022. https:\/\/news.bloombergtax.com\/payroll\/ghana-increases-minimum-wage-for-2021-and-2022."},{"issue":"S1","key":"2023071115274711400_bib31","article-title":"S129: implementation of hydroxyurea therapy for sickle cell disease on a large scale in Ghana","volume":"6","author":"Ohene-Frempong","year":"2022","journal-title":"HemaSphere"},{"issue":"9","key":"2023071115274711400_bib32","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1002\/ajh.25900","article-title":"Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: final results of the SPIN trial","volume":"95","author":"Galadanci","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"2023071115274711400_bib33","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/S2352-3026(21)00368-9","article-title":"Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial","volume":"9","author":"Abdullahi","year":"2022","journal-title":"Lancet Haematol"},{"issue":"4","key":"2023071115274711400_bib34","doi-asserted-by":"crossref","first-page":"e28906","DOI":"10.1002\/pbc.28906","article-title":"Transcranial Doppler screening in Nigerian children with sickle cell disease: a 10-year longitudinal study on the SPPIBA cohort","volume":"68","author":"Lagunju","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"2023071115274711400_bib35","unstructured":"Ghana demographics 2021---StatisticsTimes.com. Accessed 13 September 2022. https:\/\/statisticstimes.com\/demographics\/country\/ghanademographics.php."},{"issue":"Suppl 2","key":"2023071115274711400_bib36","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1542\/peds.2007-2022UUU","article-title":"Screening newborns for sickle cell disease in Ghana","volume":"121","author":"Ohene-Frempong","year":"2008","journal-title":"Pediatrics"},{"key":"2023071115274711400_bib37","unstructured":"Ghana overview: development news, research, data | World Bank. Accessed 13 September 2022. https:\/\/www.worldbank.org\/en\/country\/ghana\/overview."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/13\/3312\/2062710\/blooda_adv-2022-009049-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/13\/3312\/2062710\/blooda_adv-2022-009049-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T03:38:48Z","timestamp":1701920328000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/13\/3312\/494496\/Most-adults-with-severe-HbSC-disease-are-not"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":37,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,7,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009049","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]}}}